---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054185"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T18:58:19.782859+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical completes pivotal trial enrollment for fully implanted cochlear implant; raises $30M

## Summary
- Completed enrollment of 56 patients in U.S. pivotal trial for Acclaim cochlear implant; first three patients reach 12-month endpoint.
- Closed upsized public offering for $30M gross proceeds (up to $78M with warrants); led by Nantahala Capital and Broadfin Holdings.
- Interim data from first 10 patients: CNC word recognition improved from 15.2% to 39.2%; no serious adverse events; 24-hour wear time.
- Q1 2026 revenue $39k; R&D expense $3.6M; cash $25.3M as of March 31, 2026.
- Appointed medical device veteran Chas McKhann to Board; expanded IP portfolio to 47 patents.

## SEC filing metadata
- accession: 0001213900-26-054185
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390026054185/0001213900-26-054185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390026054185/ea0289965-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054185
- JSON: https://secwatch.observer/filing/0001213900-26-054185.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054185.txt

## Source-grounded claims
- claim_id: 2e14f2ee6d0810612ecfd0630b03f2fa4cf785c8
  claim: Envoy Medical, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $39.
  evidence_excerpt: Net Revenue was $39 for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840877/000121390026054185/0001213900-26-054185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.